I kēia lā, ke hāʻawi nei ka US Food and Drug Administration i kahi hōʻuluʻulu manaʻo o ka nūhou mai nā wahi a puni o ka ʻoihana:

• I kēia lā, ua ʻōlelo ka FDA i nā mea kūʻai aku e pili ana i ka pilikia o ka ʻai ʻana, ʻoi aku ka nui o nā keiki, onā huahana hiki ke loaʻa THC.ʻO ka ʻai ʻole ʻia ʻana o kēia mau huahana hiki ke hoʻoulu i nā hopena koʻikoʻi.
• I kēia lā, ʻo ka FDAhoopukaiahe alakaʻi hope i kapa ʻia "Ho'emi i nā pō'ino palekana mea'ai microbial i ka hana 'ana i nā hua no ka ulu 'ana: alaka'i no ka 'oihana.”Hōʻike kēia alakaʻi i nā manaʻo koʻikoʻi o FDA e pili ana i nā maʻi mai ka meaʻai e pili ana i ka ʻai ʻana i nā ʻōpuʻu maka a māmā hoʻi a hāʻawi i nā ʻoihana i nā hana i ʻōlelo ʻia e pale aku i ka moe kolohe ma ke kaulahao hana o nā hua no ka ulu ʻana.
• Ma ka Poaha, ka FDAʻae ʻia ke kālepaʻeono mau huahana paka hou ma o ke ala Premarket Tobacco Product Application (PMTA).Ua hoʻopuka ka FDAmarketing granted orders (MGO)iā RJ Reynolds Vapor Company no kāna Vuse Vibemea uila uilaa pani pū ʻia me ka ʻono pakae-wai pod, a me kāna hāmeʻa e-cigarette Vuse Ciro a me ka pani ʻana i ka ʻono paka.e-waipod.Ua hoʻopuka pū ka FDA i nā kauoha hōʻole kūʻai aku iā RJ Reynolds Vapor Company no nā Vuse Vibe a me Vuse Ciro.nā huahana e-cigarette.Eia kekahi, aia nā huahana menthol-flavored i hoʻouna ʻia e ka hui ma lalo o ka loiloi FDA.
• Ma ka Pōʻalima, ua ʻae ka FDA i ka hoʻokuʻu waha o Radicava ORS (edaravone) no ka mālama ʻana i ka amyotrophic lateral sclerosis (ALS).ʻO Racava ORS kahi mana o Racava i lawelawe waha ʻia, ʻo iai ʻae ʻia i ka makahiki 2017 ma ke ʻano he infusion intravenous (IV).e mālama i ka ALS, i kapa mau ʻia ʻo ka maʻi o Lou Gehrig.Hoʻoponopono ʻia ʻo Racava ORS a hiki ke lawe ʻia ma ka home.Ma hope o ka hoʻokē ʻai ʻana i ka pō, pono e lawe ʻia ʻo Radicava ORS i ke kakahiaka ma o ka waha a i ʻole ma o kahi paipu hānai.ʻO ka lāʻau lapaʻau waha he ʻano hoʻohālikelike like ʻo Radicava-he pōʻai lapaʻau mua o ka hoʻopaʻa ʻana i kēlā me kēia lā no 14 mau lā, a ukali ʻia e 14 mau lā lāʻau lāʻau ʻole a me nā pōʻai lapaʻau e pili ana i ka hoʻopaʻa ʻana i kēlā me kēia lā no 10 o 14 mau lā, ukali ʻia. e 14 mau lā lāʻau ʻole.ʻO nā hopena ʻaoʻao maʻamau o Radicava ʻo ia ka ʻeha (contusions), pilikia hele wāwae (gait disturbances), a me ke poʻo.ʻO ka luhi kekahi hopena ʻaoʻao mai Racava ORS.Hiki i ka Radicava a me ka Radicava ORS ke loaʻa nā hopena koʻikoʻi e pili ana i nā hopena maʻi e like me ka hives, ka ʻūlū, a me ka pōkole o ka hanu.No nā poʻe maʻi me ka naʻau sulfite, ka sodium bisulfite-he mea hoʻohui i loko o Radicava a me Racava ORS-hiki ke hoʻoulu i kahi ʻano o ka hopena maʻi e hiki ke hoʻoweliweli i ke ola.ʻO kakuhikuhi ʻikeloaʻa nā ʻike hou aku e pili ana i nā pilikia e pili ana me Radicava ORS.
• Ma ka Poalua, uaKe kikowaena o FDAno ka Drug Evaluation and Research (CDER) hoʻolaha i ka hoʻomaka ʻana o ka mea houKa Papahana Ho'ōla ma'i Rare (ARC)..ʻO ka hihiʻo o ka CDER's ARC Program ke wikiwiki nei a hoʻonui i ka hoʻomohala ʻana i nā koho lapaʻau kūpono a palekana hoʻi e hoʻoponopono ana i nā pono kūpono ʻole o nā maʻi me nā maʻi kakaʻikahi.He hoʻoikaika CDER ākea kēia me nā alakaʻi i hōʻike ʻia mai nā keʻena he nui a puni ka Center.I kona makahiki mua, e kālele ana ka CDER's ARC Program i ka hoʻoikaika ʻana i ka pilina o loko a me waho me nā mea kuleana a e hui pū me nā poʻe akamai o waho e kōkua i ka ʻike ʻana i nā hoʻonā no nā pilikia o ka ulu ʻana o ka lāʻau lapaʻau.Manaʻo maikaʻi ʻo CDER e pili ana i ka wā e hiki mai ana o ka hoʻomohala ʻana i ka lāʻau lapaʻau maʻi kakaʻikahi a ke kakali nei i ka hoʻomau ʻana i kēia hana koʻikoʻi ma lalo o ka Polokalamu CDER ARC hou - me nā maʻi, nā kahu mālama, nā hui kākoʻo, nā mea hoʻonaʻauao, nā ʻoihana, a me nā hoa ʻē aʻe - e hoʻoponopono i ka lāʻau lapaʻau nui ʻole. pono o nā maʻi a me nā ʻohana e noho ana me nā maʻi kakaʻikahi.
• Nā mea hou hoʻāʻo COVID-19:
  • I kēia lā, ua ʻae ʻia nā hoʻokolohua 432 a me nā mea hōʻiliʻili laʻana e ka FDA ma lalo o nā mana hoʻohana pilikia (EUA).He 297 mau ho'āʻo molecular a me nā mea hōʻiliʻili laʻana, 84 antibody a me nā ho'āʻo pane immune ʻē aʻe, 50 mau ho'āʻo antigen, a me 1 ho'āʻo hanu diagnostics.Aia he 77 mana molecular a me 1 mana antibody i hiki ke hoʻohana me nā laʻana i hōʻiliʻili ʻia i ka home.He 1 EUA no ka ho'āʻo molecular prescription ma ka home, 2 EUA no ka ho'āʻo antigen ma ka home, 17 EUA no nā ho'āʻo antigen over-the-counter (OTC) ma ka home, a me 3 no nā ho'āʻo OTC molecular ma ka home.
  • Ua ʻae ka FDA i nā hoʻokolohua antigen 28 a me 7 mau hoʻāʻo molecular no nā papahana screening serial.Ua ʻae pū ka FDA i nā hoʻoponopono hou ʻana o 968 i nā ʻae a EU.

ʻIke pili

ʻO ka FDA, kahi hui i loko o ka US Department ofOla kinoand Human Services, pale i ke olakino lehulehu ma ka hōʻoiaʻiʻo ʻana i ka palekana, ka pono, a me ka palekana o nā lāʻau lapaʻau kanaka a me nā lāʻau lapaʻau, nā lāʻau lapaʻau a me nā huahana olaola ʻē aʻe no ka hoʻohana kanaka, a me nā mea lapaʻau.Na ke keʻena ke kuleana no ka palekana a me ka palekana o ka lako meaʻai o ko kākou lāhui, nā mea hoʻomaʻemaʻe, nā mea hoʻohui meaʻai, nā huahana e hāʻawi ana i ka radiation uila, a no ka hoʻoponopono ʻana i nā huahana paka.